ICGEB is specifically dedicated to excellence in life sciences research and the international transfer of technologies to biotech companies. The institute has signed over 80 agreements with industrial partners in countries such as Argentina, Australia, Austria, Bangladesh, Bosnia & Herzegovina, Brazil, Canada, China, Cuba, Egypt, the United Arab Emirates, France, Germany, Japan, Jordan, India, Iran, Iceland, Italy, Kuwait, Lebanon, Moldova, Pakistan, the United Kingdom, the Dominican Republic, Russia, Serbia, Slovenia, Syria, Spain, South Africa, Sri Lanka, Turkey, Uruguay, the United States, Venezuela, and Zimbabwe. These collaborations support the production of genetically engineered pharmaceutical products (e.g., insulin, erythropoietin, interferon), diagnostic kits, and biopesticides.
ICGEB has a Regional Research Centre in Taizhou, China, and another under development in São Paulo, Brazil.
ICGEB projects strengthen expertise in epidemiological surveillance to tackle COVID-19 and other epidemics. National and international collaborations complement the broad range of technical assistance activities provided by ICGEB.
Additional collaborations have been established in areas such as the decomposition of lignocellulose for biogas production, the development of sustainable technologies for renewable energy, the creation of a new gene therapy (AAV vector-based gene therapy) for hereditary diseases, and the clinical development of a plant-extract-based drug for treating dengue fever (a tropical and subtropical viral disease transmitted by mosquitoes).
In addition to collaborating with Italian universities, ICGEB has agreements with the University of Nova Gorica (Slovenia), JNU in New Delhi (India), UCT in Cape Town (South Africa), and the Open University (UK) as institutions validating its PhD programme.